HIV-1 inhibitor-31

Cat. No.: HY-146088: Data Sheet Handling Instructions
FAQs
Technical Support

HIV-1 inhibitor-31 (compound 4) is a potent HIV-1 inhibitor. HIV-1 inhibitor-31 can be used for researching AIDS.

For research use only. We do not sell to patients.

HIV-1 inhibitor-31 Chemical Structure

CAS No. : 920036-04-0

Size		Stock
MOQ		Minimum order quantity
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote
Other size		Get quote

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All HIV Isoform Specific Products:

View All Isoforms

HIV HIV-1 HIV-2

Biological Activity
Purity & Documentation
References
Customer Review

Description

HIV-1 inhibitor-31 (compound 4) is a potent HIV-1 inhibitor. HIV-1 inhibitor-31 can be used for researching AIDS^[1].

IC₅₀ & Target

HIV-1^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
MT4	IC₅₀	13.8 nM Compound: 22	Antiviral activity against HIV1 with RT Y181C mutation in human MT4 cells in presence of 40% normal human serum Antiviral activity against HIV1 with RT Y181C mutation in human MT4 cells in presence of 40% normal human serum	[PMID: 18396399]
MT4	IC₅₀	141 nM Compound: 22	Antiviral activity against HIV1 with RT K103N/Y181C mutation in human MT4 cells in presence of 40% normal human serum Antiviral activity against HIV1 with RT K103N/Y181C mutation in human MT4 cells in presence of 40% normal human serum	[PMID: 18396399]
MT4	IC₅₀	171 nM Compound: 22	Antiviral activity against HIV1 with RT K103N/Y181C/G190A mutation in human MT4 cells in presence of 40% normal human serum Antiviral activity against HIV1 with RT K103N/Y181C/G190A mutation in human MT4 cells in presence of 40% normal human serum	[PMID: 18396399]
MT4	IC₅₀	2.6 nM Compound: 22	Antiviral activity against HIV1 with RT L100I mutation in human MT4 cells in presence of 40% normal human serum Antiviral activity against HIV1 with RT L100I mutation in human MT4 cells in presence of 40% normal human serum	[PMID: 18396399]
MT4	IC₅₀	20.3 nM Compound: 22	Antiviral activity against HIV1 with RT K103N/V179E mutation in human MT4 cells in presence of 40% normal human serum Antiviral activity against HIV1 with RT K103N/V179E mutation in human MT4 cells in presence of 40% normal human serum	[PMID: 18396399]
MT4	IC₅₀	21 nM Compound: 22	Antiviral activity against HIV1 with RT K101E/G190A mutation in human MT4 cells in presence of 40% normal human serum Antiviral activity against HIV1 with RT K101E/G190A mutation in human MT4 cells in presence of 40% normal human serum	[PMID: 18396399]
MT4	IC₅₀	21.7 nM Compound: 22	Antiviral activity against HIV1 with RT K103N/G190A mutation in human MT4 cells in presence of 40% normal human serum Antiviral activity against HIV1 with RT K103N/G190A mutation in human MT4 cells in presence of 40% normal human serum	[PMID: 18396399]
MT4	IC₅₀	23.4 nM Compound: 22	Antiviral activity against HIV1 with RT G190S mutation in human MT4 cells in presence of 40% normal human serum Antiviral activity against HIV1 with RT G190S mutation in human MT4 cells in presence of 40% normal human serum	[PMID: 18396399]
MT4	IC₅₀	29.3 nM Compound: 22	Antiviral activity against HIV1 with RT K103N/P225H mutation in human MT4 cells in presence of 40% normal human serum Antiviral activity against HIV1 with RT K103N/P225H mutation in human MT4 cells in presence of 40% normal human serum	[PMID: 18396399]
MT4	IC₅₀	35.8 nM Compound: 22	Antiviral activity against HIV1 with RT Y181C/G190A mutation in human MT4 cells in presence of 40% normal human serum Antiviral activity against HIV1 with RT Y181C/G190A mutation in human MT4 cells in presence of 40% normal human serum	[PMID: 18396399]
MT4	IC₅₀	4.7 nM Compound: 22	Antiviral activity against HIV1 in human MT4 cells in presence of 40% normal human serum Antiviral activity against HIV1 in human MT4 cells in presence of 40% normal human serum	[PMID: 18396399]
MT4	IC₅₀	7.9 nM Compound: 22	Antiviral activity against HIV1 with RT K103N mutation in human MT4 cells in presence of 40% normal human serum Antiviral activity against HIV1 with RT K103N mutation in human MT4 cells in presence of 40% normal human serum	[PMID: 18396399]
MT4	IC₅₀	9.4 nM Compound: 22	Antiviral activity against HIV1 with RT G190A mutation in human MT4 cells in presence of 40% normal human serum Antiviral activity against HIV1 with RT G190A mutation in human MT4 cells in presence of 40% normal human serum	[PMID: 18396399]
MT4	IC₅₀	> 1000 nM Compound: 22	Antiviral activity against HIV1 with RT Y188L mutation in human MT4 cells in presence of 40% normal human serum Antiviral activity against HIV1 with RT Y188L mutation in human MT4 cells in presence of 40% normal human serum	[PMID: 18396399]

Molecular Weight

410.25

Formula

C₂₁H₁₃Cl₂N₃O₂

CAS No.

920036-04-0

SMILES

N#CC1=CC(OC2=CC(OCC3=NNC4=C3C=CC=C4)=CC=C2Cl)=CC(Cl)=C1

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Xiao T, et al. Indazolyl-substituted piperidin-4-yl-aminopyrimidines as HIV-1 NNRTIs: Design, synthesis and biological activities. Eur J Med Chem. 2020;186:111864. [Content Brief]